Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 448

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 448
---
 result in such matters that may arise from time to time could have a material adverse effect on our business, results of operations, and financial condition. Our stock price is volatile. The market price of our common stock could be subject to significant fluctuations. From the completion of the Reverse Merger on August 26, 2021 through January 31, 2025, the closing price for our common stock ranged from a low of $1.21 to a high of $33.00 per share. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:

| • |     | our ability to obtain regulatory approvals for FYARRO in other indications or for any other product candidates 
 that we may develop in the future, and delays or failures to obtain such approvals;                            |

| • |     | the results of current, and any future, nonclinical or clinical trials of FYARRO or any of our product candidates 
 that we may develop in the future;                                                                                |

| • |     | the failure of FYARRO or any product candidates that we may develop in the future, if approved for marketing and 
 commercialization, to achieve commercial success;                                                                |

| • |     | any inability to obtain adequate supply of FYARRO or any of our product candidates that we may develop in the 
 future or the inability to do so at acceptable prices;                                                        |

| • |     | the entry into, or termination of, key agreements, including key licensing, supply or collaboration agreements; |

| • |     | adverse regulatory authority decisions; |

| • |     | the initiation of material developments in, or conclusion of, disputes or litigation to enforce or defend any of 
 our intellectual property rights or defend against the intellectual property rights of others;                   |

| • |     | changes in laws or regulations applicable to FYARRO or any of our product candidates that we may develop in the 
 future;                                                                                                         |

| • |     | announcements by commercial partners or competitors of new commercial products, clinical progress (or the lack 
 thereof), significant contracts, commercial relationships, or capital commitments;                             |

| • |     | failure to meet or exceed financial and development projections we may provide to the public; |

| • |     | failure to meet or exceed the financial and development projections of the investment community; |

| • |     | the perception of the pharmaceutical industry by the